ASFNR reinforced an important reality: reliable brain tumor response assessment requires imaging biomarkers that are quantitative, standardized, reproducible, and biologically validated. IB's proprietary and built-in technology #sRCBV available in IB Neuro provides automated, quantitative measurements without the variability associated with manually drawn normalization approaches. Building on this foundation, IB's #FTB maps remain the only tissue-validated solution supported by image-localized biopsy correlation to distinguish viable high-grade tumor from treatment effect. These are directly comparable across time - independent of scanner platform or field strength - enabling longitudinal reporting of treatment response. As quantitative imaging continues to evolve, the need for objective biomarkers that support patient care, clinical trials, and therapeutic development has never been greater. #ASFNR #BrainTumors #Neuroradiology #ImagingBiometrics #sRCBV #FTB

Great post! The enthusiasm around Fractional Tumor Burden (FTB) reinforces the growing need for objective imaging biomarkers in neuro-oncology. We're proud that Imaging Biometrics' FTB maps are helping clinicians tackle the challenge of progression versus pseudoprogression with greater confidence, automation, and quantification. #ASFNR26 #BrainTumor #NeuroOncology #FTB

This is exactly the challenge advanced imaging was designed to address: moving beyond what can be seen visually on conventional MRI toward objective, quantitative biomarkers that better reflect what's happening within the tumor. We look forward to the results of the #GABLE trial. #GBM #BrainTumor #NeuroOncology #FTB #IBNeuro

Distinguishing tumor progression from treatment effect remains one of the most challenging problems in neuro-oncology. Quantitative biomarkers such as @ImgBiometrics' IB Neuro (standardized rCBV), IB DCE (permeability), IB Diffusion, and IB Delta T1 maps can provide objective insight beyond what conventional MRI alone can show. Thanks to Blackford for highlighting this important clinical challenge. #NeuroOncology #MRI #Radiology

Our September newsletter is out! Inside this issue: • The ECOG-ACRIN EAF223/GABLE glioblastoma imaging biomarker study • Kathleen Schmainda, PhD, at ESMRMB 2026 • Dr. Schmainda’s 2026 Hector F. DeLuca Scientific Achievement Award • IB Nimble 2 and connected multidisciplinary care • QSMetric™ and expanding access to quantitative susceptibility mapping • Where to find Imaging Biometrics at ASFNR 2026 Read the September issue: mailchi.mp/imagingbiometrics… #QuantitativeMRI #NeuroOncology #Glioblastoma #BrainTumorImaging #MedicalImaging #MRI #Neuroradiology #ImagingBiometrics

Looking forward to Dr. Yi Wang's EMTP 2026 presentation, "Overview of Clinical Applications of QSM." Dr. Wang's pioneering contributions have helped shape the field of QSM, and we're proud to work with him by offering QSMetric™, an FDA-cleared, automated, and patented platform, to advance quantitative imaging biomarkers in clinical practice. #QSM #QSMetric #MRI #EMTP2026

Looking forward to #ASFNR2026!

Excited to see Kathleen Schmainda, PhD, co-founder of @ImgBiometrics, speaking at the GliMR Pre-Day Lunch Symposium. A pioneer in quantitative neuroimaging and imaging biomarkers for brain tumors, Dr. Schmainda will discuss how advanced MRI techniques can bring greater objectivity to neuro-oncology care. #GliMR #NeuroOncology #MRI #BrainTumors #Radiology #ESMRMB

Explore the Imaging Biometrics YouTube channel for educational videos on advanced brain MRI, DSC perfusion, standardized rCBV, Fractional Tumor Burden, and more. Watch and subscribe: youtube.com/@ImagingBiometri… #MRI #Neuroimaging #Radiology #BrainTumor #MedicalImaging

Appreciate the Musella Foundation / @VirtualTrials further highlighting the Phase 1 results for oral gallium maltolate in recurrent #GBM: virtualtrials.org/newsarticl… Strong safety profile + OS ~16 months, with long-term survivors >30 months. Early data—but highlights the value of continuing innovation in this space. Encouraging early signal in a difficult disease. #glioblastoma #neurooncology #braincancer #clinicaltrials

The Problem with Conventional MRI. There's up to a 40% disagreement in post-treatment MRI interpretation—why? Conventional MRI remains the foundation of brain tumor imaging—but it has limitations. Post-treatment changes, inflammation, and blood products can all mimic tumor progression. This leads to variability in interpretation and uncertainty in clinical decision-making. Advanced imaging isn’t about replacing MRI—it’s about making it more reliable, quantitative, and actionable. At Imaging Biometrics, our focus is simple: ➡️ Reduce ambiguity ➡️ Standardize results ➡️ Support confident clinical decisions

Imaging interpretation turnaround times more than double over a decade radiologybusiness.com/topics… MR is up 256%. CT is up 318%. Radiologists are maxed out. @ImgBiometrics delivers fully automated quantitative maps — objective, reproducible, and available within seconds of acquisition. As radiology faces soaring volume and shrinking workforce capacity, IB provides what the system can’t: speed, standardization, and true scalability. If the specialty has hit its limit, the answer isn’t more hours — it’s automation that removes variability and accelerates interpretation.

Congratulations to Dr. Mona Al‑Gizawiy of the Medical College of Wisconsin on securing a new NIH R01 award—and to announce our role as a sub‑award recipient on this important project. This five‑year, $3M grant will accelerate the understanding of gallium maltolate (GaM), a promising oral therapy targeting some of the most aggressive pediatric brain cancers. Under Dr. Al‑Gizawiy’s leadership, the pre-clinical project will advance the combination of GaM with radiation therapy, building on early evidence that GaM can enhance treatment effectiveness. IB will support this work with our FDA‑cleared quantitative MR imaging platform—including our advanced Fractional Tumor Burden (FTB) maps—which delivers standardized, highly sensitive measures of tumor response. This capability is essential for evaluating emerging therapies and represents a key differentiator in the neuro‑oncology imaging market. “IB’s quantitative imaging gives us an early and reliable window into how tumors respond to treatment—something conventional scans simply can’t match,” said Dr. Al‑Gizawiy. IB packages pre-clinical imaging workflows to create a unified imaging ecosystem that strengthens our position across research and clinical markets. This initiative supports long‑term growth by expanding IB’s footprint in translational research and multi‑site trials. #PediatricBrainCancer #ChildhoodCancerResearch #PediatricOncology #BrainTumorResearch #DIPG #Glioblastoma #ATRT #HighGradeGlioma #ftbmaps

Everyone knows manual normalization of MR DSC perfusion is the Achilles’ heel of neuro MRI—subjective, inconsistent, and impossible to reproduce across scanners or sites. Yet the industry still pretends it’s “good enough.” It isn’t. @ImgBiometrics eliminated this problem years ago. Our fully quantitative, harmonized imaging makes MRI exams truly comparable anywhere. If decentralized neuro imaging is the goal, manual normalization is the roadblock—and IB is the way past it. Shift toward imaging outside the hospital could save billions radiologybusiness.com/topics…

Imaging Biometrics’ FTB technology is now part of a Phase 2 GBM trial at MD Anderson/Cooper University! Proud to support innovations that may reshape GBM care. proactiveinvestors.co.uk/com…